ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Abstract

PURPOSE:

To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888.

EXPERIMENTAL DESIGN:

In vitro potency was determined in a PARP-1 and PARP-2 enzyme assay. In vivo efficacy was evaluated in syngeneic and xenograft models in combination with temozolomide, platinums, cyclophosphamide, and ionizing radiation.

RESULTS:

ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with K(i)s of 5.2 and 2.9 nmol/L, respectively. The compound has good oral bioavailability and crosses the blood-brain barrier. ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model. PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d. In the 9L orthotopic rat glioma model, temozolomide alone exhibited minimal efficacy, whereas ABT-888, when combined with temozolomide, significantly slowed tumor progression. In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited. Finally, ABT-888 potentiated radiation (2 Gy/d x 10) in an HCT-116 colon carcinoma model. In each model, ABT-888 did not display single-agent activity.

CONCLUSIONS:

ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. This broad spectrum of chemopotentiation and radiopotentiation makes this compound an attractive candidate for clinical evaluation.

• Authors: Cherrie K Donawho, Yan Luo, Yanping Luo, Thomas D Penning, Joy L Bauch, Jennifer J Bouska, Velitchka D Bontcheva-Diaz, Bryan F Cox, Theodore L DeWeese, Larry E Dillehay, Debra C Ferguson, Nayereh S Ghoreishi-Haack, David R Grimm, Ran Guan, Edward K Han, Rhonda R Holley-Shanks, Boris Hristov, Kenneth B Idler, Ken Jarvis, Eric F Johnson, Lawrence R Kleinberg, Vered Klinghofer, Loren M Lasko, Xuesong Liu, Kennan C Marsh, Thomas P McGonigal, Jonathan A Meulbroek, Amanda M Olson, Joann P Palma, Luis E Rodriguez, Yan Shi, Jason A Stavropoulos, Alan C Tsurutani, Gui-Dong Zhu, Saul H Rosenberg, Vincent L Giranda, David J Frost
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 13 Issue 9 Pg. 2728-37 (May 01 2007) ISSN: 1078-0432 [Print] United States
• PMID: 17473206 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Alkylating
• Benzimidazoles
• Enzyme Inhibitors
• Poly(ADP-ribose) Polymerase Inhibitors
• veliparib

Topics

• Administration, Oral
• Animals
• Antineoplastic Agents, Alkylating (therapeutic use)
• Benzimidazoles (administration & dosage, pharmacokinetics)
• Biological Availability
• Blood-Brain Barrier (metabolism)
• Cell Line, Tumor
• DNA Damage
• Disease Models, Animal
• Dogs
• Drug Synergism
• Enzyme Inhibitors (administration & dosage, pharmacokinetics)
• Female
• Haplorhini
• Humans
• Male
• Mice
• Mice, Inbred Strains
• Neoplasms (drug therapy)
• Poly(ADP-ribose) Polymerase Inhibitors
• Rats
• Rats, Inbred Strains
• Xenograft Model Antitumor Assays